Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | KDR |
| Variant | amp |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | KDR (VEGFR2) amplification indicates an increased number of copies of the KDR (VEGFR2) gene. However, the mechanism causing the increase is unspecified. |
| Associated Drug Resistance | |
| Category Variants Paths |
KDR amp |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR amp | lung non-small cell carcinoma | no benefit | Vandetanib | Phase III | Actionable | In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684). | 26578684 |